Bellicum Pharmaceuticals, Inc., a Houston, Texas-based developer of therapeutic vaccines and other immunotherapeutic approaches for the treatment of cancer and chronic infectious diseases, raised $4.5m in Series A and Convertible Note funding.
The funds will be used to complete the company’s ongoing Phase I/IIa trial of BP-GMAX-CD1 in patients with advanced, androgen independent prostate cancer, and to prepare for Phase IIb trials.
Commenting on the financing, Bellicum Founder, President & Chief Medical Officer Kevin M. Slawin, M.D., said: “Thanks to the support of our current and new investors, we are now in a strong position to realize the significant potential of our lead product to positively impact the lives of men living with prostate cancer”.
These funds bring the total raised to date to $8.5m, including $1.45m from the Texas Emerging Technology Fund, $6.8m from angel investors, and additional seed capital from founders.
FinSMEs
02/11/2009